Pipeline

NI101SQ is a novel subcutaneous version of aducanumab, formulated for autoinjector self-administration.It is a human monoclonal antibody against beta amyloid in development for the treatment of Alzheimer's disease. In 2024, Neurimmune regained global rights from Biogen to NI101SQ and the entire aducanumab portfolio.

*The U.S. FDA granted accelerated approval for intravenously administered aducanumab-avwa for the treatment of Alzheimer’s disease.

ALXN2220 (formerly NI006), is a human antibody that exclusively targets with high affinity the disease-associated amyloid conformation but not physiological forms of transthyretin. ALXN2220 targets both wild-type ATTR as well as ATTR mutants that are linked to hereditary forms of ATTR cardiomyopathy (ATTR-CM) and ATTR polyneuropathy. ALXN2220 induces the clearance of pathological ATTR in preclinical models. Currently, ALXN2220 is in Phase 3 clinical development (NCT06183931). The U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 for the treatment of ATTR-CM.

In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop ALXN2220 (NI006). >>Link to announcement

AP-101 is a human antibody directed against misfolded superoxide dismutase 1 (SOD1). Currently, safety, tolerability, pharmacokinetics and pharmacodynamics of AP-101 are assessed in patients with ALS. Neurimmune and TVM Capital Life Science created AL-S Pharma AG to develop AP-101 to human proof-of-concept. AL-S Pharma engages with Chorus, an autonomous unit of Eli Lilly and Company, to execute on an innovative clinical plan in collaboration with an international network of ALS experts.

NSC001 is developed by Neurimmune’s collaboration partner NSC Therapeutics GmbH. It is a small, rigid, chemical analog of the cholinergic neurotransmitter acetylcholine in development for the treatment of patients with cholinergic deficits. NSC Therapeutics GmbH received $5 mio funding from the Alzheimer’s Disease Drug Discovery Foundation to support upcoming Phase 2 proof of concept clinical trials.

NI008 is a human antibody specifically targeting pathological protein produced by a mutant C9orf72 gene. The antibody showed in preclinical models to lower neuroinflammation, slow neurodegeneration and lengthen survival in the most common genetic form of amyotrophic lateral sclerosis, or ALS, and frontotemporal dementia, or FTD.

NG004 is a human antibody blocking the function of Nogo-A, one of the most potent and well-studied nerve growth inhibitors. NG004 is developed by NovaGo Therapeutics for the treatment of spinal cord injury. Novago Therapeutics is a spin-off company from the University of Zurich that entered into a strategic partnership with Neurimmune to discover human antibodies targeting Nogo-A. NovaGo Therapeutics was founded by Prof. Martin Schwab based on the discovery of the existence of “inhibitors of nerve fiber growth” as a cause of the absence of regeneration of injured fiber tracts in the central nervous system.

NI203 is a human antibody that targets pathologic IAPP aggregates and neutralizes their toxicity. In preclinical models of type-2 diabetes NI203 supported normal beta cell functions resulting in re-stored insulin secretion and reduction of the type-2 diabetes symptoms.